0
Abstract: Poster Presentations |

UTILITY OF A HIGH-FREQUENCY CHEST WALL OSCILLATION (HFCWO) TRIAL PERIOD TO ASSESS TREATMENT SATISFACTION, ADHERENCE AND BENEFIT IN PATIENTS WITH COPD FREE TO VIEW

Diane L. Kachel, BA*; Cynthia S. Davey, MS; Timothy C. Kennedy, MD; Victor L. Marchione, MD; Mark W. Rolfe, MD; Mark J. Rumbak, MD
Author and Funding Information

Hill-Rom, St Paul, MN


Chest


Chest. 2005;128(4_MeetingAbstracts):252S. doi:10.1378/chest.128.4_MeetingAbstracts.252S
Text Size: A A A
Published online

Abstract

PURPOSE:  To evaluate the utility of a short-term therapy trial to assess individual use and potential benefit of HFCWO in patients with COPD prior to extending therapy for long-term use.

METHODS:  Consenting patients with COPD, FEV1%<70%, retained secretions, dyspnea and reduced physical functioning were trained to use an HFCWO airway clearance device twice daily at home (N=94, 3 centers). Medical history, physical exam, spirometry, dyspnea, functional capacity, and quality of life (QOL) assessments were taken at baseline and after 90-days of therapy. Periodic symptom assessments and treatment satisfaction/adherence data were also collected.

RESULTS:  Patients with moderate to severe COPD that completed the trial demonstrated improvements in symptoms, 6-min walk distance (6-MWD, p<0.001) and role-physical domain (SF-36, p<0.004). Analysis of inter-group differences between patients who continued or discontinued HFCWO after trial completion indicated a higher, sustained level of treatment satisfaction and adherence within the group that continued HFCWO long-term. Improvements in dyspnea (Borg, p<0.009; BDI/TDI, p<0.003), 6-MWD (p<0.001) and QOL (general health, vitality and physical functioning, p<0.05) were also significantly higher. Compared to baseline, a clinically significant improvement in 6-MWD (182±34 ft further) was demonstrated. Patients with moderate COPD demonstrated greater improvements in functional capacity after 90 days of HFCWO therapy than those with severe disease. Baseline predictors of success for specific outcomes are being assessed.

CONCLUSION:  In this prospective, cohort study, COPD patients completing a 90-day trial of HFCWO demonstrated improvements in symptoms, functional capacity and QOL. Patients who did not perceive treatment benefit were less adherent and more likely to discontinue. Patients who reported a higher level of treatment tolerance and effectiveness within the first week were more likely to demonstrate significant improvements after 90 days of therapy.

CLINICAL IMPLICATIONS:  Select patients with COPD adhere well to daily HFCWO therapy and may benefit from regular airway clearance therapy. A HFCWO therapy trial can help identify patients who are more likely to be adherent and satisfied with this therapy. Improvements in functional capacity and QOL may warrant consideration for long-term use.

DISCLOSURE:  Diane Kachel, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543